ReviewCancer drug resistance (Alhambra, Calif.)2026

TROP2-targeting antibody-drug conjugates in breast cancer and ovarian carcinoma: therapeutic advances and resistance mechanisms.

Pilar Eroles et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.